1. Introduction {#sec1}
===============

In recent years, microRNAs (miRNAs) have received great attention in cancer research. MiRNAs are small noncoding RNAs, usually 20--23 nucleotide (nt) long, which regulate the expression of protein-coding genes at the posttranscriptional level. Studies have also shown that aberrant miRNA expression is involved in the development and progression of cancer \[[@B1]--[@B3]\]; thus miRNAs could be used as biomarkers for diagnosis and prognosis of cancer, and targets for cancer molecular therapy \[[@B4]--[@B6]\]. Nevertheless, there is still a lot remaining to be understood in the involvement of miRNAs in carcinogenesis and progression of cancer. Among all the cancer-related miRNAs, miR-221 was reported to be increasingly expressed in various carcinomas, compared with nontumoral tissues \[[@B7]--[@B9]\]. However, as a noninvasive method, detection of the circulating miRNA biomarkers in plasma or serum samples is more acceptable than those in tissue specimens.

To assess the cumulative evidence regarding the possible association between elevated circulating miR-221 and poor survival in patients with cancer and to discuss the possibility to apply miR-221 as a prognostic marker, we conducted a systematic review and meta-analysis of relevant studies investigating this association.

2. Methods {#sec2}
==========

2.1. Data Sources {#sec2.1}
-----------------

The study was performed following the guidelines of the Meta-analysis of Observational Studies in Epidemiology group (MOOSE) \[[@B10]\]. We carefully searched online PubMed, EMBASE, and Cochrane Library up to August 2013 to identify relevant studies. Two sets of keywords used in this search were "(miR-221 and cancer) or (miRNAs and cancer prognosis)" with limits to article types other than review, human species, and English language.

2.2. Study Selection {#sec2.2}
--------------------

All identified studies were examined by 2 authors (M-H Rong and G.Chen) independently. Studies were considered eligible if they met the following criteria: (1) they were published in a peer-reviewed journal; (2) they studied the patients with any type of carcinoma; (3) they reported miR-221 expression in blood, plasma, or serum; and (4) they investigated the association between miR-221 expression levels and survival outcome. The exclusion criteria for the current meta-analysis were that studies (1) reporting the survival data of a set of miRNAs but not miR-221 alone, (2) analyzing nondichotomous miR-221 expression levels, (3) without key information such as hazard ratio (HR), 95%* *CI and *P* value, and (4) were laboratory studies.

2.3. Data Extraction {#sec2.3}
--------------------

The following information from each paper was extracted by an author (M-H Rong) and then confirmed by another author (G. Chen): first author, publish year, country of publication, type of carcinoma, clinical stage of disease, number of patients, specimen, measurement and cutoff of miR-221, survival analysis, HR, 95% CI and *P* value, and time of followup. These extracted data were double checked by Y-W Dang. Additionally, we emailed to the authors of studies for the data needed for the meta-analytic calculations.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistics were conducted by the Stata 11.0 statistical software. The random effect model was used to calculate the pooled HR and its 95% CI. The heterogeneity test of combined HR was evaluated via the *I*-square test and Chi-square. A two-tailed *P* value of \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Four Hundred and Forty-Eight Cases Were Involved in Meta-Analysis {#sec3.1}
----------------------------------------------------------------------

Two hundred and twenty-eight records for miR-221 and cancer were identified from a primary literature search in PubMed, EMBASE, and Cochrane Library. After manually screening the titles, abstracts, and key words, two hundred and twelve studies were excluded because they were review articles, letters, non-English articles, laboratory studies, or studies irrelevant to the current analysis. Of the sixteen candidate studies, one study investigated a set of miRNAs but not miR-221 alone; two studies did not deal with miR-221 expression data as a dichotomic variable; one lacked the key HR data; and other eight had no survival outcome. Therefore, the final meta-analysis was carried out for the remaining four studies \[[@B11]--[@B14]\] ([Figure 1](#fig1){ref-type="fig"}). The main features of eligible studies are summarized in [Table 1](#tab1){ref-type="table"}. We collected data from 4 studies including a total of 448 participants from the United States and China. All of them were retrospective in design. The patients were of four types of carcinomas, including colorectal cancer (CRC) \[[@B11]\], nonsmall cell lung carcinoma (NSCLC) \[[@B12]\], hepatocellular carcinoma (HCC) \[[@B13]\], and NK/T-cell lymphoma (NTCL) \[[@B14]\]. Quantitative real-time PCR (qRT-PCR) was applied for miR-221 expression assessment in all the studies included. Plasma or serum samples were examined to determine miR-221 expression level, while both the two samples were tested in one study \[[@B12]\]. In addition, the cut-off values of miR-221 were based on Youden index (two studies), median (one study), or 4.8-fold (one study). Overall survival (OS) was evaluated in all the studies.

3.2. Lack of Significant Association between miR-221 Expression and Poor Overall Survival {#sec3.2}
-----------------------------------------------------------------------------------------

There was significant heterogeneity among studies (*x* ^2^ for heterogeneity = 25.32, *I*-square = 84.2%, *P* = 0.000, and Freedom = 4). The results of meta-analysis suggested that no significant difference in poor overall survival between miR-221 high and low groups (OR = 0.94, 95% CI = 0.47--1.87, *Z* = 0.17, and *P* = 0.863) ([Figure 2](#fig2){ref-type="fig"}). Since there were less than five prognostic studies in the current analysis, publication bias of the studies included was not performed.

4. Discussion {#sec4}
=============

Extensive profiling studies over the past several years have shown that various miRNAs are differentially expressed in different classes of cancers. Among them, miR-221 is considered as a microoncogene. MiR-221 plays an important role in epithelial-to-mesenchymal transition (EMT). It has been identified as a basal-like subtype-specific miRNA that downregulates the expression of epithelial-specific genes and enhances the expression of mesenchymal-specific genes. Furthermore, miR-221 increases cell migration and invasion \[[@B15]--[@B17]\]. The basal-like transcription factor, FOSL1, can directly stimulate the transcription of miR-221 \[[@B17]\]. The abundance of miR-221 reduces with the suppression of mitogen-activated or extracellular signal-regulated protein kinase (MEK) \[[@B17]\]. The miR-221-mediated reduction in E-cadherin is dependent on the targeting of the 3′-UTR of trichorhinophalangeal syndrome type 1 (TRPS1). TRPS1 inhibits EMT by directly repressing the expression of Zinc finger E-box-binding homeobox 2 (ZEB2) \[[@B18]\]. Thus, miR-221 could contribute to the aggressive clinical behavior of various types of cancers.

Other crucial validated miR-221 target genes include an oncosuppressor p27^Kip1^ and a key transcription factor, Slug. Interference with the process of Slug/miR-221 upregulation and p27^Kip1^ downregulation can be accomplished using antisense miRNA (antagomiR or miRNA inhibitor) molecules targeting miR-221, inducing the downregulation of Slug and the upregulation of p27^Kip1^ \[[@B19]--[@B21]\]. This may provide new therapeutic options for cancers when systematic delivery of anti-miR-221 is achievable.

Overexpression of miR-221 has been confirmed in several malignancies, including HCC \[[@B22]\], breast cancer \[[@B23]\], prostate carcinoma \[[@B24]\], colorectal carcinoma \[[@B25]\], melanoma \[[@B26]\], and acute myeloid leukemia \[[@B27]\]. High level of miR-221 expression is correlated with metastasis, tumor capsular infiltration, tumor stage \[[@B22], [@B28], [@B29]\], and poor prognosis \[[@B30], [@B31]\]. Although many miRNAs are expressed in tumor tissues and tumor cells, the development of such miRNAs being biomarkers requires a more convenient approach of studying peripheral blood, rather than tissue collection. Circulating prognostic markers should be more valuable for detection throughout life of patients with carcinoma. Some miRNAs were recently identified in serum and plasma in a remarkably stable form that is protected from endogenous RNase activity \[[@B6], [@B32]\]. The current study aims to provide a comprehensive evaluation on the association between serum/plasma of miR-221 expression and survival of carcinomas based on published references available. However, the results of this meta-analysis demonstrate that there is no significant difference in poor overall survival (OR = 0.94, 95% CI = 0.47--1.87, *Z* = 0.17, and *P* = 0.863) between high and low miR-221 in patients with carcinoma. It is unlikely that serum/plasma miR-221 overexpression is an independent prognostic factor for tumor prognosis.

However, this review has heterogeneity and several limitations. First, the number of studies included in the study is relatively small. The pooled HR was calculated on the basis of 4 studies with a small sample size of 448 cases. Second, many factors including cut-off definition of miR-221 and tumor clinical stage which may influence the tumor progression are not considered in the meta-analysis. Third, we did not consider sample size in trials, which can vary in the studies included. Smaller number in trials might give different results compared to larger trials for disease progression. For instance, the number of the cases in the study of Heegaard et al. \[[@B12]\] was approximately 5 times that in the study of Li et al. \[[@B13]\]. The publication bias was not excluded either. Another potential limitation of this study is that there was marked heterogeneity in the modes of treatment used in each study and response rates. Considerable between-study heterogeneity was observed probably due to the reasons listed above.

Despite these caveats, this meta-analysis demonstrates the equivalence of high and low miR-221 expression for carcinomas in terms of survival.

5. Conclusions {#sec5}
==============

In conclusion, a causal effect of plasma/serum miR-221 expression on tumor prognosis is unlikely, given the apparent lack of an association based on current small numbers of studies and patients. Future studies with a large number of cases are recommended to further validate the role of circulating miR-221 as the prognostic indicator for patients with carcinoma.
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###### 

Summary information of references included in the meta-analysis of miR-221 and survival.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                       Year   Country   Study design   Type of carcinoma   Stage   Number of samples   Specimen   miR-221 assay   Cutoff         Survival analysis   Followup, months   Hazard ratios   CI            *P*
  ---------------------------- ------ --------- -------------- ------------------- ------- ------------------- ---------- --------------- -------------- ------------------- ------------------ --------------- ------------- -------
  Pu et al. \[[@B11]\]         2010   China     R              CRC                 I--IV   103                 Plasma     qRT-PCR         Youden index   OS                  60                 Reported\       1.04--11.65   0.043
                                                                                                                                                                                                3.48                          

  Heegaard et al. \[[@B12]\]   2012   USA       R              NSCLC               I-II    220                 Serum      qRT-PCR         median         OS                  60                 AP\             0.40--1.01    0.053
                                                                                                                                                                                                0.63                          

  Heegaard et al. \[[@B12]\]   2012   USA       R              NSCLC               I-II    220                 Plasma     qRT-PCR         median         OS                  60                 AP\             0.59--1.45    0.723
                                                                                                                                                                                                0.92                          

  Li et al. \[[@B13]\]         2011   China     R              HCC                 I--IV   46                  Serum      qRT-PCR         4.8-fold       OS                  60                 Reported\       1.24--2.98    0.018
                                                                                                                                                                                                1.90                          

  Guo et al. \[[@B14]\]        2010   China     R              NTCL                I--IV   79                  Plasma     qRT-PCR         Youden index   OS                  60                 Reported\       0.06--0.56    0.003
                                                                                                                                                                                                0.18                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R: retrospective; CRC: colorectal cancer; NSCLC: nonsmall cell lung carcinoma; HCC: hepatocellular carcinoma; NTCL: NK/T-cell lymphoma; OS: overall survival; AP: author provided.
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